TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...
TG Therapeutics (TGTX) stock surged 17% on Mar. 3 after the company reported revenue that topped Wall Street estimates. The company reported Q4 earnings per share of 15 cents, falling short of the ...
Zacks Investment Research on MSN1d
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?TG Therapeutics TGTX shares soared 10.2% in the last trading session to close at $40.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...
TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology 2025 annual meeting in San Diego, California ...
TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. $TGTX insiders have traded $TGTX ...
Biopharma firm TG Therapeutics sees stock surge as revenue beats estimates and plans for new Briumvi trial take shape ...
The better-than-expected results were due almost entirely to robust sales of the company's one commercialized drug, multiple sclerosis treatment Briumvi. One development that helped was the drug's ...
TG Therapeutics (NasdaqCM:TGTX) saw its share price surge by 28% last week following a robust earnings announcement. The company's fourth-quarter revenue grew by 146% year-over-year, accompanied by a ...
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectivelyTarget guidance of approximately $540 ...
TG Therapeutics, a biotechnology company focused on developing and commercializing innovative therapies for diverse patient populations, has reported outstanding fourth-quarter (Q4) and full-year 2024 ...
Reports Q4 revenue $108.185M, consensus $100.67M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2024 was a year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback